Neutral
●
GlobeNewsWire
●
4 months ago
PHILADELPHIA & VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the closing of its best-efforts offering of 1,449,300 common shares. Each common share was sold at an offe...